首页 > 最新文献

Prescrire International最新文献

英文 中文
Sonidegib (Odomzo°) and extensive basal cell carcinoma. Sonidegib (Odomzo°)和广泛基底细胞癌。
Q4 Medicine Pub Date : 2017-01-01
{"title":"Sonidegib (Odomzo°) and extensive basal cell carcinoma.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":"26 178","pages":"14-15"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36937495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statins: increased risk of type 2 diabetes. 他汀类药物:增加2型糖尿病的风险。
Q4 Medicine Pub Date : 2017-01-01

Five meta-analyses of double-blind randomised comparative clinical trials have shown a small but statistically significant increase in the risk of type 2 diabetes in statin users. The relative risk was about 1.1. One add- itional case of diabetes occurred for approximately every 255 patients treated with a statin for 4 years. The risk is dose-dependent. It was observed with all the statins studied, including pravastatin, simvastatin, atorvastatin and rosuvastatin. In practice, the risk of diabetes is not a reason for choosing one statin rather than another. When statin ther- apy is justified, pravastatin and simva- statin remain the statins of choice.

五项双盲随机对照临床试验的荟萃分析显示,他汀类药物服用者患2型糖尿病的风险略有增加,但在统计学上具有显著意义。相对风险约为1.1。大约每255名接受他汀类药物治疗4年的患者中就有1例新增糖尿病病例。这种风险与剂量有关。所有研究的他汀类药物,包括普伐他汀、辛伐他汀、阿托伐他汀和瑞舒伐他汀,都观察到了这一点。实际上,患糖尿病的风险并不是选择一种他汀类药物而不选择另一种的原因。当他汀类药物治疗是合理的,普伐他汀和辛伐他汀仍然是他汀类药物的选择。
{"title":"Statins: increased risk of type 2 diabetes.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Five meta-analyses of double-blind randomised comparative clinical trials have shown a small but statistically significant increase in the risk of type 2 diabetes in statin users. The relative risk was about 1.1. One add- itional case of diabetes occurred for approximately every 255 patients treated with a statin for 4 years. The risk is dose-dependent. It was observed with all the statins studied, including pravastatin, simvastatin, atorvastatin and rosuvastatin. In practice, the risk of diabetes is not a reason for choosing one statin rather than another. When statin ther- apy is justified, pravastatin and simva- statin remain the statins of choice.</p>","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":"26 178","pages":"18-19"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36937496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pseudoephedrine: ischaemic colitis. 伪麻黄碱:缺血性结肠炎。
Q4 Medicine Pub Date : 2017-01-01
{"title":"Pseudoephedrine: ischaemic colitis.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":"26 178","pages":"20"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36984178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osteoarthritis of the knee. 膝骨关节炎。
Q4 Medicine Pub Date : 2017-01-01 DOI: 10.1007/978-2-287-74175-3
McCallie Ave. Chattanooga
{"title":"Osteoarthritis of the knee.","authors":"McCallie Ave. Chattanooga","doi":"10.1007/978-2-287-74175-3","DOIUrl":"https://doi.org/10.1007/978-2-287-74175-3","url":null,"abstract":"","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":"55 1","pages":"78"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85732718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Hypertension Targeting 120 mmHg: survival benefit after 3 years, but high renal risk. 高血压目标为120mmhg: 3年后生存获益,但肾脏风险高。
Q4 Medicine Pub Date : 2017-01-01

In a randomised trial, reducing the systolic blood pressure target to around 120 mmHg led to a reduction in all-cause mortality compared to a tar- get of around 135 mmHg: after about 3 years, 3.3% of patients in the "inten- sive" treatment group had died versus 4.5% in the "standard" treatment group. The trial was not blinded, however.The patients included were aged 50 years or older, at high risk of cardiovascular events, often overweight but not dia- betic, and had no history of stroke or symptomatic heart failure. This survival benefit was accompan- ied by a twofold increase in serious adverse effects, in particular renal effects, and cannot be extrapolated to the majority of hypertensive patients.

在一项随机试验中,将收缩压目标降低到120毫米汞柱左右,与135毫米汞柱左右的目标相比,全因死亡率降低:大约3年后,3.3%的“强化”治疗组患者死亡,而4.5%的“标准”治疗组患者死亡。然而,该试验并不是盲法的。纳入的患者年龄在50岁或以上,有心血管事件的高风险,通常超重但没有糖尿病,没有中风或症状性心力衰竭的病史。这种生存获益伴随着严重不良反应的两倍增加,特别是肾脏影响,不能推断为大多数高血压患者。
{"title":"Hypertension Targeting 120 mmHg: survival benefit after 3 years, but high renal risk.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In a randomised trial, reducing the systolic blood pressure target to around 120 mmHg led to a reduction in all-cause mortality compared to a tar- get of around 135 mmHg: after about 3 years, 3.3% of patients in the \"inten- sive\" treatment group had died versus 4.5% in the \"standard\" treatment group. The trial was not blinded, however.The patients included were aged 50 years or older, at high risk of cardiovascular events, often overweight but not dia- betic, and had no history of stroke or symptomatic heart failure. This survival benefit was accompan- ied by a twofold increase in serious adverse effects, in particular renal effects, and cannot be extrapolated to the majority of hypertensive patients.</p>","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":"26 178","pages":"21-22"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36984177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Taking missing data into account in everyday practice. 在日常实践中考虑缺失数据。
Q4 Medicine Pub Date : 2017-01-01

Ideally, health professionals would have all the necessary information at their disposal for making healthcare decisions, but in reality they lack a great deal of clinically relevant data. Some of these missing data simply cannot, or cannot yet, exist. In other cases, the data are missing because the healthcare professional was unable to find them even though they are available, because they have not been generated even though they could have been, because they have not been published, or because they have been concealed. In most cases, when data on medi- cal interventions are suspected or known to be missing, this can be taken into account by assuming that the supposed benefits of the interven- tion are overestimated, while its harms are underestimated. When several drugs appear to have a similar harm-benefit balance, it is better to choose those for which fewer data are missing, or those which have the longest clinical use.

理想情况下,卫生专业人员应该掌握所有必要的信息,以便做出医疗保健决定,但实际上,他们缺乏大量的临床相关数据。其中一些缺失的数据根本不可能存在,或者还不可能存在。在其他情况下,数据丢失是因为医疗保健专业人员无法找到它们,即使它们是可用的,因为它们没有生成,即使它们可以生成,因为它们没有发布,或者因为它们被隐藏了。在大多数情况下,当怀疑或已知缺少关于医疗干预的数据时,可以通过假设干预的假定益处被高估,而其危害被低估来考虑这一点。当几种药物似乎具有相似的危害-收益平衡时,最好选择那些缺少数据较少的药物,或者那些临床使用时间最长的药物。
{"title":"Taking missing data into account in everyday practice.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Ideally, health professionals would have all the necessary information at their disposal for making healthcare decisions, but in reality they lack a great deal of clinically relevant data. Some of these missing data simply cannot, or cannot yet, exist. In other cases, the data are missing because the healthcare professional was unable to find them even though they are available, because they have not been generated even though they could have been, because they have not been published, or because they have been concealed. In most cases, when data on medi- cal interventions are suspected or known to be missing, this can be taken into account by assuming that the supposed benefits of the interven- tion are overestimated, while its harms are underestimated. When several drugs appear to have a similar harm-benefit balance, it is better to choose those for which fewer data are missing, or those which have the longest clinical use.</p>","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":"26 178","pages":"23-27"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36984181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Out of the frying pan, into the fire. 刚出油锅,又入火坑。
Q4 Medicine Pub Date : 2017-01-01
{"title":"Out of the frying pan, into the fire.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":"26 178","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36937489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benzodiazepines: dementia in the elderly?. 苯二氮卓类药物:老年人痴呆?
Q4 Medicine Pub Date : 2017-01-01

About twenty benzodiazepines and related drugs, such as zolpidem and zopiclone, are used to treat sleep dis- orders and anxiety, and also as anti- convulsants.Their short-term adverse effects include confusion and cogni- tive disorders that regress only slow- ly after treatment withdrawal, especial- ly in elderly patients. Questions have been raised as to persistent cognitive effects in case of long-term benzo- diazepine exposure. A case-control study of 1796 patients over 66 years of age showed that benzodiazepine exposure 5 to 10 years previously was statistically significant- ly more frequent among those who developed Alzheimer's disease. Five other epidemiological studies provided similar results. However, some studies showed no relation with the duration of exposure or the cumu- lative dose; this is an argument against a causal relationship between benzodiazepine use and dementia. These studies provide only weak evidence and thus fail to establish a causal relationship. In addition, early symptoms of dementia can cause anx- iety, which may lead to benzodiazepine prescription in the period preceding diagnosis.The results of these studies do not, however, rule out a long-term risk of persistent cognitive impair- ment. In practice, the known adverse effects of benzodiazepines are a suf- ficient reason to avoid these drugs, especially in elderly patients. The pos- sibility of irreversible cognitive impair- ment is another reason not to pre- scribe them.

大约有20种苯二氮卓类药物和相关药物,如唑吡坦和唑匹克隆,用于治疗睡眠障碍和焦虑,也用作抗惊厥药。短期不良反应包括精神错乱和认知障碍,停药后恢复缓慢,尤其是老年患者。对于长期服用苯二氮卓类药物是否会产生持续的认知影响,人们提出了一些问题。一项对1796名66岁以上患者的病例对照研究表明,在患阿尔茨海默病的患者中,5至10年前接触苯二氮卓类药物的频率具有统计学意义。其他五项流行病学研究也提供了类似的结果。然而,一些研究显示与暴露时间或累积剂量无关;这是一个反对苯二氮卓类药物使用与痴呆之间因果关系的论点。这些研究只提供了微弱的证据,因此无法建立因果关系。此外,痴呆症的早期症状可引起焦虑,这可能导致在诊断前的一段时间服用苯二氮卓类药物。然而,这些研究的结果并不能排除持续性认知损害的长期风险。在实践中,苯二氮卓类药物已知的不良反应是避免使用这些药物的充分理由,特别是在老年患者中。不可逆转的认知损伤的可能性是不开这些药的另一个原因。
{"title":"Benzodiazepines: dementia in the elderly?.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>About twenty benzodiazepines and related drugs, such as zolpidem and zopiclone, are used to treat sleep dis- orders and anxiety, and also as anti- convulsants.Their short-term adverse effects include confusion and cogni- tive disorders that regress only slow- ly after treatment withdrawal, especial- ly in elderly patients. Questions have been raised as to persistent cognitive effects in case of long-term benzo- diazepine exposure. A case-control study of 1796 patients over 66 years of age showed that benzodiazepine exposure 5 to 10 years previously was statistically significant- ly more frequent among those who developed Alzheimer's disease. Five other epidemiological studies provided similar results. However, some studies showed no relation with the duration of exposure or the cumu- lative dose; this is an argument against a causal relationship between benzodiazepine use and dementia. These studies provide only weak evidence and thus fail to establish a causal relationship. In addition, early symptoms of dementia can cause anx- iety, which may lead to benzodiazepine prescription in the period preceding diagnosis.The results of these studies do not, however, rule out a long-term risk of persistent cognitive impair- ment. In practice, the known adverse effects of benzodiazepines are a suf- ficient reason to avoid these drugs, especially in elderly patients. The pos- sibility of irreversible cognitive impair- ment is another reason not to pre- scribe them.</p>","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":"26 178","pages":"16-17"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36937494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RTS,S/AS01E malaria vaccine (MoSQUIRIX*) Children living in malaria-endemic regions: little efficacy, poorly documented harms. RTS,S/AS01E疟疾疫苗(MoSQUIRIX*):生活在疟疾流行地区的儿童:疗效甚微,危害记录不足。
Q4 Medicine Pub Date : 2017-01-01

Malaria remains a major public health problem in most tropical coun- tries. Plasmodium falciparum infection can be life-threatening, especially in children. Insecticide-treated bed nets have been shown to reduce deaths due to malaria among young children. A malaria vaccine (RTS,S/AS01E) containing two adjuvants has been assessed for its ability to prevent P. falciparum malaria among young children living in endemic areas. The clinical data have been analysed by the European Medicines Agency (EMA) in conjunction with the World Health Organization (WHO). Efficacy has been evaluated in sub-Saharan African countries. Two trials including a total of more than 16 000 children aged 6 weeks to 17 months compared the malaria vac- cine with a rabies vaccine or a menin- gococcal vaccine. Most of the children were healthy, had ready access to healthcare, and were protected with bed nets. In these trials, three injections of the malaria vaccine one month apart did not reduce overall mortality or malaria mortality in low-mortality settings. In the year following vaccina- tion, the risk of malaria episodes was reduced by about 30% among children aged 6 to 12 weeks and by about 50% among those aged 5 to 17 months.The incidence of severe malaria was only reduced in the older age group. Vac- cine efficacy waned rapidly over time, even with a booster dose at 18 months. During clinical trials, reactions at the injection site and systemic reac- tions were more frequent with the malaria vaccine than with the compara- tor vaccines. Febrile seizures during the days following vaccination were 2 to 5 times more frequent with the malaria vaccine among children aged 5 to 17 months. The malaria vaccine may also carry a risk of meningitis, as well as a risk of pneumonia among HIV-infected children and premature infants.

在大多数热带国家,疟疾仍然是一个主要的公共卫生问题。恶性疟原虫感染可危及生命,尤其是儿童。经杀虫剂处理的蚊帐已被证明可以减少幼儿因疟疾而死亡的人数。一种含有两种佐剂的疟疾疫苗(RTS,S/AS01E)对生活在流行地区的幼儿预防恶性疟原虫疟疾的能力进行了评估。临床数据已由欧洲药品管理局(EMA)与世界卫生组织(世卫组织)联合分析。已在撒哈拉以南非洲国家对疗效进行了评估。两项试验将疟疾疫苗与狂犬病疫苗或脑膜炎球菌疫苗进行了比较,其中包括16,000多名年龄在6周到17个月之间的儿童。大多数儿童都很健康,可以随时获得保健服务,并得到蚊帐的保护。在这些试验中,间隔一个月注射三次疟疾疫苗并没有降低总死亡率或低死亡率环境中的疟疾死亡率。在接种疫苗后的一年中,6至12周龄儿童的疟疾发作风险降低了约30%,5至17个月儿童的疟疾发作风险降低了约50%。严重疟疾的发病率仅在老年群体中有所下降。随着时间的推移,疫苗的效力迅速减弱,即使在18个月时接种加强剂量也是如此。在临床试验期间,疟疾疫苗在注射部位的反应和全身反应比对照疫苗更频繁。在5至17个月的儿童中,接种疟疾疫苗后数日内发热性惊厥的发生率高出2至5倍。疟疾疫苗也可能在感染艾滋病毒的儿童和早产儿中带来脑膜炎的风险以及肺炎的风险。
{"title":"RTS,S/AS01E malaria vaccine (MoSQUIRIX*) Children living in malaria-endemic regions: little efficacy, poorly documented harms.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Malaria remains a major public health problem in most tropical coun- tries. Plasmodium falciparum infection can be life-threatening, especially in children. Insecticide-treated bed nets have been shown to reduce deaths due to malaria among young children. A malaria vaccine (RTS,S/AS01E) containing two adjuvants has been assessed for its ability to prevent P. falciparum malaria among young children living in endemic areas. The clinical data have been analysed by the European Medicines Agency (EMA) in conjunction with the World Health Organization (WHO). Efficacy has been evaluated in sub-Saharan African countries. Two trials including a total of more than 16 000 children aged 6 weeks to 17 months compared the malaria vac- cine with a rabies vaccine or a menin- gococcal vaccine. Most of the children were healthy, had ready access to healthcare, and were protected with bed nets. In these trials, three injections of the malaria vaccine one month apart did not reduce overall mortality or malaria mortality in low-mortality settings. In the year following vaccina- tion, the risk of malaria episodes was reduced by about 30% among children aged 6 to 12 weeks and by about 50% among those aged 5 to 17 months.The incidence of severe malaria was only reduced in the older age group. Vac- cine efficacy waned rapidly over time, even with a booster dose at 18 months. During clinical trials, reactions at the injection site and systemic reac- tions were more frequent with the malaria vaccine than with the compara- tor vaccines. Febrile seizures during the days following vaccination were 2 to 5 times more frequent with the malaria vaccine among children aged 5 to 17 months. The malaria vaccine may also carry a risk of meningitis, as well as a risk of pneumonia among HIV-infected children and premature infants.</p>","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":"26 178","pages":"5-8"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36937490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Olaparib (LYNPARZAO) Ovarian cancer: spare patients who are in remission. 奥拉帕尼(LYNPARZAO)卵巢癌:缓解期患者备用。
Q4 Medicine Pub Date : 2017-01-01

Standard post-surgical (adjuvant) chemotherapy for ovarian cancer is based on a platinum salt, and may be repeated if relapse occurs more than six months after the end of chemo- therapy. Olaparib inhibits enzymes involved in DNA repair. It is claimed to have an antitumour effect, especially in the presence of deleterious BRCA muta- tions. Olaparib has been authorised in the EU for continuous single-agent therapy after the end of platinum-based chemotherapy in patients with "plati- num-sensitive" BRCA-positive ovarian cancer who have already received at least two lines of platinum-based che- motherapy and entered complete or partial remission after the last course of treatment. Clinical evaluation of olaparib is based on a randomised, double-blind, placebo-controlled trial in 265 patients who were recruited regardless of their BRCA status. After a median follow-up of 37 months, patients treated with olaparib showed no survival advan- tage, whether or not their tumour harboured BRCA mutations. The time to radiological progression was pro- longed by several months. An inher- ently unreliable post hoc analysis suggested that olaparib delayed the need for further chemotherapy. Olaparib exposes these patients in remission to frequent adverse effects, including nausea, vomiting, and impaired haematopoiesis. Olaparib can also cause life-threatening myelo- dysplastic syndrome, acute myeloid leukaemia, and haemorrhage. Olaparib is metabolised in the liver, mainly by cytochrome P450 isoenzymes CYP3A4 and CYP3A5. It is also a P-glycoprotein substrate and is likely to inhibit CYP3A4, P-glycopro- tein and other carrier proteins. Multiple pharmacokinetic interactions are also likely. Treatment with olaparib requires patients to take eight capsules twice a day, between meals. In practice, in early 2016, expectations of patients with ovarian cancer who have received at least two lines of chemotherapy are high, as they have short life expectancy and no sat- isfactory treatment options. Yet treat- ment with olaparib after the end of platinum-based chemotherapy still has an unfavourable harm-benefit bal- ance: patients derive no proven ben- efit, but adverse effects are frequent and sometimes fatal.

卵巢癌的标准术后(辅助)化疗基于铂盐,如果化疗结束后超过6个月复发,可以重复化疗。奥拉帕尼抑制参与DNA修复的酶。据称它具有抗肿瘤作用,特别是在存在有害的BRCA突变的情况下。奥拉帕尼已被欧盟批准用于“铂敏感”brca阳性卵巢癌患者在铂基化疗结束后的持续单药治疗,这些患者已经接受了至少2线铂基化疗,并在最后一个疗程后进入完全或部分缓解。奥拉帕尼的临床评估基于一项随机、双盲、安慰剂对照试验,该试验招募了265名患者,无论其BRCA状态如何。中位随访37个月后,无论患者的肿瘤是否携带BRCA突变,接受奥拉帕尼治疗的患者都没有表现出生存优势。放射学进展的时间延长了几个月。一项本质上不可靠的事后分析表明奥拉帕尼延缓了进一步化疗的需要。奥拉帕尼使这些处于缓解期的患者暴露于频繁的不良反应,包括恶心、呕吐和造血功能受损。奥拉帕尼还可引起危及生命的骨髓发育不良综合征、急性髓性白血病和出血。奥拉帕尼在肝脏代谢,主要通过细胞色素P450同工酶CYP3A4和CYP3A5。它也是p糖蛋白底物,可能抑制CYP3A4、p糖蛋白和其他载体蛋白。多种药代动力学相互作用也可能存在。用奥拉帕尼治疗需要患者每天两次服用8粒胶囊,在两餐之间服用。在实践中,在2016年初,卵巢癌患者接受至少两线化疗的期望很高,因为他们的预期寿命较短,没有令人满意的治疗选择。然而,在铂类化疗结束后用奥拉帕尼治疗仍然存在不利的利弊平衡:患者没有得到证实的益处,但不良反应是频繁的,有时是致命的。
{"title":"Olaparib (LYNPARZAO) Ovarian cancer: spare patients who are in remission.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Standard post-surgical (adjuvant) chemotherapy for ovarian cancer is based on a platinum salt, and may be repeated if relapse occurs more than six months after the end of chemo- therapy. Olaparib inhibits enzymes involved in DNA repair. It is claimed to have an antitumour effect, especially in the presence of deleterious BRCA muta- tions. Olaparib has been authorised in the EU for continuous single-agent therapy after the end of platinum-based chemotherapy in patients with \"plati- num-sensitive\" BRCA-positive ovarian cancer who have already received at least two lines of platinum-based che- motherapy and entered complete or partial remission after the last course of treatment. Clinical evaluation of olaparib is based on a randomised, double-blind, placebo-controlled trial in 265 patients who were recruited regardless of their BRCA status. After a median follow-up of 37 months, patients treated with olaparib showed no survival advan- tage, whether or not their tumour harboured BRCA mutations. The time to radiological progression was pro- longed by several months. An inher- ently unreliable post hoc analysis suggested that olaparib delayed the need for further chemotherapy. Olaparib exposes these patients in remission to frequent adverse effects, including nausea, vomiting, and impaired haematopoiesis. Olaparib can also cause life-threatening myelo- dysplastic syndrome, acute myeloid leukaemia, and haemorrhage. Olaparib is metabolised in the liver, mainly by cytochrome P450 isoenzymes CYP3A4 and CYP3A5. It is also a P-glycoprotein substrate and is likely to inhibit CYP3A4, P-glycopro- tein and other carrier proteins. Multiple pharmacokinetic interactions are also likely. Treatment with olaparib requires patients to take eight capsules twice a day, between meals. In practice, in early 2016, expectations of patients with ovarian cancer who have received at least two lines of chemotherapy are high, as they have short life expectancy and no sat- isfactory treatment options. Yet treat- ment with olaparib after the end of platinum-based chemotherapy still has an unfavourable harm-benefit bal- ance: patients derive no proven ben- efit, but adverse effects are frequent and sometimes fatal.</p>","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":"26 178","pages":"9-12"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36937491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Prescrire International
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1